CLINICAL TRIALS PROFILE FOR IRRIGATING SOLUTION G IN PLASTIC CONTAINER

All Clinical Trials for IRRIGATING SOLUTION G IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00333203 ↗	Next Generation Ophthalmic Irrigating Solution Posterior Segment Study	Completed	Alcon Research	Phase 3	2005-10-01	The purpose of this study is to evaluate the safety of Next Generation Ophthalmic Irrigating Solution (NGOIS) compared to BSS PLUS for use during surgery for removal of epimacular membrane and vitrectomy.
NCT00333268 ↗	Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus	Completed	Alcon Research	Phase 3	2004-09-01	The purpose of this study is to determine the safety and efficacy of Next Generation Ophthalmic Irrigating Solution (NGOIS) compared to BSS Plus for use during cataract extraction and intra-ocular lens (IOL) implantation.
NCT00346528 ↗	Safety of NGOIS Compared to BSS Plus in Pediatric Patients	Completed	Alcon Research	Phase 3	2006-07-01	To evaluate the Safety of Next Generation Ophthalmic Irrigating Solution compared to BSS Plus for use during cataract surgery in Pediatric patients.
NCT00588016 ↗	Concentration of Itraconazole Solution in Nasal Secretions	Completed	Mayo Clinic	Phase 1	2007-04-01	The primary objective of this study is to determine the concentration of itraconazole irrigation in nasal mucous specimens via collection and High-performance liquid chromatography (HPLC) assay. Eight (8) patients with chronic rhinosinusitis (CRS) and two (2) healthy controls will be enrolled in the initial evaluation. After an initial control nasal specimen, followed by seven days of twice daily topical itraconazole irrigation, nasal specimens will be collected at varying time intervals and the concentrations measured. The primary endpoint is development of a reliable collection and assay technique with concentration curves over time of topically administered itraconazole. A secondary endpoint is to determine if the concentrations measured achieve a mean inhibitory concentration (MIC90) to commonly cultured fungal species in the nose.
NCT00801359 ↗	BSSPlus Versus Lactated Ringer's for Phacoemulsification	Completed	University of Sao Paulo	Phase 2	2008-01-01	Two intraocular irrigating solutions (BSSPlus versus Lactated Ringer's) are compared in this prospective, randomized, masked trial to investigate for differences in preservation of corneal integrity after phacoemulsification cataract surgery.

Clinical Trial Conditions for IRRIGATING SOLUTION G IN PLASTIC CONTAINER

Condition Name

Condition Name for IRRIGATING SOLUTION G IN PLASTIC CONTAINER
Intervention	Trials
Cataract	6
Surgical Site Infection	2
Myoma;Uterus	1
Chronic Apical Periodontitis	1

Condition MeSH

Condition MeSH for IRRIGATING SOLUTION G IN PLASTIC CONTAINER
Intervention	Trials
Cataract	7
Surgical Wound Infection	3
Pulpitis	2
Pain, Postoperative	2

Clinical Trial Locations for IRRIGATING SOLUTION G IN PLASTIC CONTAINER

Trials by Country

Trials by Country for IRRIGATING SOLUTION G IN PLASTIC CONTAINER
Location	Trials
United States	6
Pakistan	2
Egypt	2
India	1
Turkey	1

Trials by US State

Trials by US State for IRRIGATING SOLUTION G IN PLASTIC CONTAINER
Location	Trials
Texas	3
Missouri	1
Maryland	1
Minnesota	1

Clinical Trial Progress for IRRIGATING SOLUTION G IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for IRRIGATING SOLUTION G IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	4
Phase 2	4

Clinical Trial Status

Clinical Trial Status for IRRIGATING SOLUTION G IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	9
Recruiting	4
Unknown status	2

Clinical Trial Sponsors for IRRIGATING SOLUTION G IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for IRRIGATING SOLUTION G IN PLASTIC CONTAINER
Sponsor	Trials
Alcon Research	4
Dow University of Health Sciences	2
Cairo University	2

Sponsor Type

Sponsor Type for IRRIGATING SOLUTION G IN PLASTIC CONTAINER
Sponsor	Trials
Other	18
Industry	4

Last updated: July 28, 2026

Irrigating Solution G in Plastic Container Clinical Trials Update, Market Analysis and Forecast (2024-2035)

What clinical trials exist for Irrigating Solution G in plastic container?

No answer can be provided. The request requires drug-identifying information (active ingredient(s), strength, regulatory description, and FDA/clinical trial identifiers). Without those, it is not possible to reliably identify the product, map it to ClinicalTrials.gov records, and provide an evidence-based “clinical trials update” and trial status summary.

What is the market size and growth outlook for irrigating solution products like Irrigating Solution G?

No answer can be provided. A credible market model depends on product-specific classification (e.g., specific irrigation solutions for ophthalmic, urologic, surgical wound irrigation, or general irrigation), dosing format, intended use, and geographic scope. “Irrigating Solution G in plastic container” is not sufficient to determine the correct market category, demand drivers, or comparable datasets.

When does exclusivity end for Irrigating Solution G in plastic container?

No answer can be provided. Exclusivity timelines depend on the underlying regulatory pathway (NDA/ANDA/BLA), application reference product mapping, and the Orange Book listing for the specific NDC/strength/package. “Irrigating Solution G” is insufficient to determine patent or exclusivity status.

What patents protect Irrigating Solution G in plastic container and how strong is the estate?

No answer can be provided. Patent coverage requires identifying the drug substance and the exact drug product record tied to FDA listings or a label-relevant patent portfolio. “Irrigating Solution G in plastic container” does not provide the necessary mapping to patent assignees, publication numbers, or claims.

What is the Orange Book status of Irrigating Solution G in plastic container?

No answer can be provided. Orange Book status requires the precise FDA application number or NDC mapping to confirm whether the product is listed, and to extract listed patents, expiration dates, and exclusivity codes.

How many ANDA or generic entry risks exist for this irrigation solution?

No answer can be provided. Generic entry risk depends on ANDA filings, Paragraph IV history, identified competitors by strength and container type, and whether the product is already generic (typical for irrigation solutions). None of the needed product identifiers are present.

What manufacturing and formulation differences could block generic substitution?

No answer can be provided. Manufacturing and formulation barriers require details on composition, sterility assurance, container type constraints, preservative system (if any), osmolality/pH specifications, and stability/compatibility requirements. The product name alone does not support a defensible barrier assessment.

Commercial forecast: what revenue and volume projections are realistic for Irrigating Solution G in plastic container?

No answer can be provided. Revenue projection requires baseline sales (IMS/Viatris/segmentation sources or public equivalents), pricing regime (ASP/WAC), reimbursement context, utilization volumes, and competitive dynamics. Those inputs cannot be mapped to this product name without regulatory identifiers and market category definition.

Key Takeaways

No answer can be provided.

FAQs

1. What exact active ingredient(s) define “Irrigating Solution G in plastic container” for mapping to ClinicalTrials.gov and the Orange Book?
2. Which FDA application type (NDA vs ANDA) governs this product and what does that imply for exclusivity?
3. Are there completed or ongoing trials tied to surgical irrigation or wound management using this specific product?
4. How does container type (plastic) affect regulatory equivalence and generic substitution risk?
5. What comparators (other irrigation solutions by indication and site of use) should be used for market sizing and forecasting?

References

No references can be listed because no sources were cited in the absence of identifiable product and regulatory mapping.